AMGEN INC Quarterly Deferred Income Tax Expense (Benefit) in USD from Q1 2015 to Q1 2018

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Amgen Inc annual/quarterly Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2015 to Q1 2018.
  • Amgen Inc Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2018 was -$72M, a 6.49% increase year-over-year.
  • Amgen Inc annual Deferred Income Tax Expense (Benefit) for 2023 was -$1.22B, a 4.71% increase from 2022.
  • Amgen Inc annual Deferred Income Tax Expense (Benefit) for 2022 was -$1.28B, a 194% decline from 2021.
  • Amgen Inc annual Deferred Income Tax Expense (Benefit) for 2021 was -$434M, a 19.6% decline from 2020.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2018 -$72M +$5M +6.49% Jan 1, 2018 Mar 31, 2018 10-Q 2018-04-25
Q1 2017 -$77M -$9M -13.2% Jan 1, 2017 Mar 31, 2017 10-Q 2018-04-25
Q1 2016 -$68M -$23M -51.1% Jan 1, 2016 Mar 31, 2016 10-Q 2017-04-27
Q1 2015 -$45M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.